| Dr Ashley Renee Cole, MD | |
|
590 Medical Center Dr, Fort Payne, AL 35968 | |
| (256) 997-2526 | |
| Not Available |
| Full Name | Dr Ashley Renee Cole |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 15 Years |
| Location | 590 Medical Center Dr, Fort Payne, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841424959 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | R2106 (Kentucky) | Secondary |
| 207P00000X | Emergency Medicine | MD.31554 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dekalb Regional Medical Center | Fort payne, AL | Hospital |
| Russell Medical Center | Alexander city, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Nes Tennessee, Inc. | 3678472040 | 46 |
| Thomasville Regional Medical Associates Llc | 4688096266 | 12 |
| Em Transform, Llc | 6507216454 | 14 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Paragon Contracting Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225071459 PECOS PAC ID: 3971417825 Enrollment ID: O20050218000756 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Fort Payne Clinic Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396764395 PECOS PAC ID: 5698779304 Enrollment ID: O20060912000391 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Nes Tennessee, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437606605 PECOS PAC ID: 3678472040 Enrollment ID: O20161031002328 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Fort Payne Hbp Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740748821 PECOS PAC ID: 7618201302 Enrollment ID: O20190701000565 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Dekalb Urgent Care And Wellness Clinic, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073150306 PECOS PAC ID: 4880022508 Enrollment ID: O20200311002666 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Rose Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841823432 PECOS PAC ID: 9830528017 Enrollment ID: O20200409001738 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Hospitalist Medicine Physicians Of Alabama-tcg, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144709601 PECOS PAC ID: 6608289368 Enrollment ID: O20210119002835 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas-tcg Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902384464 PECOS PAC ID: 3678825312 Enrollment ID: O20210707000263 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Thomasville Regional Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972231314 PECOS PAC ID: 4688096266 Enrollment ID: O20221020002815 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Entity Name | Em Transform, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285417154 PECOS PAC ID: 6507216454 Enrollment ID: O20231219002105 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ashley Renee Cole, MD 590 Medical Center Dr Sw, Fort Payne, AL 35968-3418 Ph: (256) 997-2526 | Dr Ashley Renee Cole, MD 590 Medical Center Dr, Fort Payne, AL 35968 Ph: (256) 997-2526 |
News Archive
Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early, researchers say.
The Substance Abuse and Mental Health Services Administration (SAMHSA) will unveil the results of the latest (2009) National Survey on Drug Use and Health (NSDUH) at a press conference on Thursday, September 16. The annual survey is the largest of its kind, and is the government's primary vehicle for determining how many persons are abusing illegal drugs, pharmaceuticals, alcohol and tobacco.
IncellDx, Inc., a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases, has closed $3 million dollars in Series A financing. Proceeds from the financing will be used to advance the commercialization of IncellDx™ products and to initiate the US clinical trial for HPV OncoTect®, a E6, E7 mRNA test that is currently CE marked.
An international group of researchers on board a mobile laboratory equipped with an innovative handheld genetic sequencing device are tracking the movement of the Zika virus since it disembarked in Brazil and began spreading through the Americas.
Gilead Sciences, Inc. today announced new data from the open-label phase of two pivotal Phase III clinical trials (Studies 102 and 103) evaluating the four-year efficacy of Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B virus (HBV) infection.
› Verified 2 days ago
Dr. Robert W Theakston, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 Greenhill Blvd Nw, Fort Payne, AL 35967 Phone: 256-845-9355 | |
Dr. Thomas Roy Mcfarland, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 200 Medical Center Dr, Fort Payne, AL 35968 Phone: 256-845-3150 | |
Dr. Tony Arland White, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 590 Medical Center Dr Sw, Suite 190, Fort Payne, AL 35968 Phone: 256-997-2526 Fax: 256-997-2553 | |
Dr. Ronald E. Graham, D.O. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 Medical Center Dr, Fort Payne, AL 35968 Phone: 256-845-3150 | |
Marlon Chad Williamson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 617 Gault Ave N, Fort Payne, AL 35967 Phone: 256-979-1633 Fax: 256-304-5456 |